DT Investment Partners LLC Purchases 32 Shares of Eli Lilly and Company (NYSE:LLY)

DT Investment Partners LLC increased its position in Eli Lilly and Company (NYSE:LLY) by 5.1% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 654 shares of the company’s stock after buying an additional 32 shares during the quarter. DT Investment Partners LLC’s holdings in Eli Lilly and Company were worth $422,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of LLY. Lipe & Dalton bought a new position in Eli Lilly and Company in the 4th quarter worth $26,000. Thompson Investment Management Inc. bought a new position in shares of Eli Lilly and Company during the 3rd quarter valued at about $27,000. Retirement Group LLC boosted its holdings in shares of Eli Lilly and Company by 159.1% during the 2nd quarter. Retirement Group LLC now owns 57 shares of the company’s stock valued at $27,000 after purchasing an additional 35 shares during the last quarter. Cornerstone Planning Group LLC bought a new position in shares of Eli Lilly and Company during the 2nd quarter valued at about $33,000. Finally, Legacy Financial Group LLC purchased a new stake in shares of Eli Lilly and Company during the 3rd quarter valued at about $35,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 2.6 %

Shares of NYSE LLY traded down $19.64 during midday trading on Friday, reaching $726.31. 3,505,526 shares of the company’s stock traded hands, compared to its average volume of 2,202,924. The company has a market cap of $690.11 billion, a price-to-earnings ratio of 125.23, a P/E/G ratio of 1.63 and a beta of 0.34. Eli Lilly and Company has a one year low of $369.76 and a one year high of $800.78. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The stock’s 50 day simple moving average is $763.96 and its 200-day simple moving average is $659.59.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.19. The company had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. Eli Lilly and Company’s revenue was up 28.1% compared to the same quarter last year. During the same period last year, the firm earned $2.09 earnings per share. On average, analysts predict that Eli Lilly and Company will post 12.52 EPS for the current fiscal year.

Insider Buying and Selling at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 54,032 shares of Eli Lilly and Company stock in a transaction on Monday, January 29th. The shares were sold at an average price of $645.07, for a total transaction of $34,854,422.24. Following the completion of the sale, the insider now directly owns 99,488,598 shares in the company, valued at $64,177,109,911.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 0.13% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on LLY. Bank of America upped their target price on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research report on Friday, March 1st. DZ Bank lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective on the stock. in a research report on Wednesday, February 21st. The Goldman Sachs Group increased their price objective on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research report on Thursday, April 11th. BMO Capital Markets increased their price objective on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 7th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a research report on Friday, March 15th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and an average price target of $728.05.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.